High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition
Laurel T. Bate-Eya(University of Oxford), M. Emmy M. Dolman(University of Amsterdam)
Cited by 61
Related Papers
High-Throughput Screening Identifies Idasanutlin as a Resensitizing Drug for Venetoclax-Resistant Neuroblastoma Cells
|Molecular Cancer Therapeutics|2021|18